SKYE Skye Bioscience Inc

Price (delayed)

$0.7602

Market cap

$26.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.44

Enterprise value

$18.88M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I ...

Highlights
Skye Bioscience's debt has decreased by 24% YoY but it has increased by 14% QoQ
The company's quick ratio has shrunk by 85% YoY and by 48% QoQ
The equity has plunged by 85% YoY and by 55% from the previous quarter

Key stats

What are the main financial stats of SKYE

SKYE stock price

How has the Skye Bioscience stock price performed over time
Intraday
-1.29%
1 week
-10.55%
1 month
-12.62%
1 year
-66.06%
YTD
1.4%
QTD
23.69%

Financial performance

How have Skye Bioscience's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$59.08M
Net income
-$57.33M
Gross margin
N/A
Net margin
N/A
Skye Bioscience's net income has shrunk by 76% YoY and by 2.5% QoQ
SKYE's operating income has plunged by 65% YoY

Price vs fundamentals

How does SKYE's price correlate with its fundamentals

Growth

What is Skye Bioscience's growth rate over time

Valuation

What is Skye Bioscience stock price valuation
P/E
N/A
P/B
2.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SKYE's EPS has dropped by 73% year-on-year and by 2.1% since the previous quarter
The equity has plunged by 85% YoY and by 55% from the previous quarter
SKYE's P/B is 14% above its last 4 quarters average of 2.5

Efficiency

How efficient is Skye Bioscience business performance
The ROIC has soared by 71% YoY but it has contracted by 27% from the previous quarter
The company's return on equity has shrunk by 51% QoQ
The ROA has decreased by 35% from the previous quarter

Dividends

What is SKYE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SKYE.

Financial health

How did Skye Bioscience financials performed over time
The total assets is 87% greater than the total liabilities
The company's total liabilities has surged by 88% YoY and by 26% QoQ
The company's quick ratio has shrunk by 85% YoY and by 48% QoQ
Skye Bioscience's debt is 97% lower than its equity
The debt to equity has soared by 200% from the previous quarter and by 200% YoY
The equity has plunged by 85% YoY and by 55% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.